deltatrials
Unknown PHASE1 INTERVENTIONAL NCT00004207

Liposomal Daunorubicin in Treating Patients With Metastatic Breast Cancer

A Phase I Study to Determine the Maximum Tolerated Dose of Daunoxome as Therapy for the Treatment of Metastatic Breast Cancer

Sponsor: University of Leicester

Conditions Breast Cancer
Interventions liposomal daunorubicin citrate
Updated 5 times since 2017 Last updated: Jun 23, 2014 Started: Dec 31, 1997
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Breast Cancer, this trial is ongoing. The trial is conducted by University of Leicester and has accumulated 5 data snapshots since 1997. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotUnknown Status~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE1

    First recorded

Dec 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Leicester
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations